3 Results for "

aSyn aggregation

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "aSyn aggregation" in MCE Product Catalog:

Cat. No.: HY-125287
CAS No.: 1802518-63-3
Purity:  99.87%
Synonyms: (Rac)-UCB0599; NPT200-11
Target:  

α-synuclein

Research Areas:  

Neurological Disease

(Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .
loading...
    loading...
Cat. No.: HY-P5082
CAS No.: 2243207-00-1
Target:  

α-synuclein

Research Areas:  

Neurological Disease

α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .
loading...
    loading...
Cat. No.: HY-186260
CAS No.: 3132328-83-4
Target:  

Potassium Channel

Research Areas:  

Neurological Disease

TMEM175 agonist 6 (Compound F-101) is a TMEM175 agonist. TMEM175 agonists can restore/enhance the function of lysosomes and reduce aSyn aggregation, thus being applicable for the research of diseases such as Parkinson's disease .
loading...
    loading...